Table 2.
Adverse Events with an Attribution of at Least Possible Occurring in Greater than 15% of Patients Who Received Study Treatment (N = 17) Based on National Cancer Institute Common Terminology Criteria for Adverse Events (Version 4.0)
| No. Patients (%) | ||||
|---|---|---|---|---|
| Adverse Event | All Grades (Gr 1–3) | Grade 1 | Grade 2 | Grade 3 |
| Concentration Impairment | 14 (82) | 9 (53) | 4 (24) | 1 (6) |
| Fatigue | 11 (65) | 3 (18) | 8 (47) | 0 (0) |
| Tremor | 10 (59) | 9 (53) | 1 (6) | 0 (0) |
| Nausea | 9 (53) | 7 (41) | 0 (0) | 2 (12) |
| Dizziness | 6 (35) | 3 (18) | 1 (6) | 2 (12) |
| Blurred Vision | 4 (24) | 3 (18) | 1 (6) | 0 (0) |
| Hypotension | 4 (24) | 1 (6) | 2 (12) | 1 (6) |
| Vomiting | 3 (18) | 3 (18) | 0 (0) | 0 (0) |
| Edema (limbs) | 3 (18) | 2 (12) | 1 (6) | 0 (0) |
| Fall | 3 (18) | 1 (6) | 1 (6) | 1 (6) |
| Gait Disturbance | 3 (18) | 3 (18) | 0 (0) | 0 (0) |
| Malaise | 3 (18) | 0 (0) | 3 (18) | 0 (0) |
| Presyncope | 3 (18) | 0 (0) | 3 (18) | 0 (0) |